Transfusion-related acute lung injury: From bedside to bench and back

Blood

Volumn 117, Issue 5, 2011, Pages 1463-1471

  Shaz, Beth H ^a,b   Stowell, Sean R ^b   Hillyer, Christopher D ^a,c  

^a NEW YORK BLOOD CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD40 ANTIGEN; CD40 LIGAND; FRESH FROZEN PLASMA; HLA ANTIGEN CLASS 1 ANTIBODY; HLA ANTIGEN CLASS 2 ANTIBODY; HUMAN NEUTROPHIL ANTIGEN 1A ANTIBODY; HUMAN NEUTROPHIL ANTIGEN 1B ANTIBODY; HUMAN NEUTROPHIL ANTIGEN 2 ANTIBODY; HUMAN NEUTROPHIL ANTIGEN 3A ANTIBODY; LEUKOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; AUTOPSY; BLOOD; BLOOD DONOR; CELL ACTIVATION; ERYTHROCYTE TRANSFUSION; HUMAN; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; LUNG EDEMA; LUNG ENDOTHELIUM; NEUTROPHIL; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRANSFUSION RELATED ACUTE LUNG INJURY;

EID: 79551639702     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-278135     Document Type: Review

References (85)

1. Yomtovian R, Kline W, Press C, et al. Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody. Lancet. 1984;1(8371):244-246. (Pubitemid 14178523)
2. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25(6):573-577.
3. US Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2009. Rockville, MD: United States Department of Health and Human Services, 2010.
4. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774-1789.
5. Flesland O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med. 2007;33(suppl 1):S17-21.
6. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol. 2007;136(6):788-799. (Pubitemid 46348408)
7. Sachs UJ. Pathophysiology of TRALI: current concepts. Intensive Care Med. 2007;33(suppl 1):S3-S11.
8. Doan CA. The recognition of a biologic differentiation in the white blood cells: with especial reference to blood transfusion. JAMA. 1926;86:1593-1597.
9. Brittingham TE, Chaplin H Jr. Febrile transfusion reactions caused by sensitivity to donor leukocytes and platelets. JAMA. 1957;165:819-825.
10. Philipps E, Fleischner FG. Pulomonary edema in the course of a blood transfusion without overloading the circulation. Dis Chest. 1966;50(6):619-623.
11. Ward HN, Lipscomb TS, Cawley LP. Pulmonary hypersensitivity reaction after blood transfusion. Arch Intern Med. 1968;122(4):362-366.
12. Zoon KC. Transfusion related acute lung injury letter. Rockville, MD: US Food and Drug Administration, 2001.
13. Blood Products Advisory Committee. Topic II: Transfusion Related Acute Lung Injury (TRALI). Washington, DC: 2007.
14. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406-3417.
15. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005;33(4):721-726.
16. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care. 1994;9:72-81.
17. Triulzi DJ. Transfusion-related acute lung injury: current concepts for the clinician. Anesth Analg. 2009;108(3):770-776.
18. Centers for Disease Control and Prevention. The national healthcare safety network (NHSN) manual: biovigilance component: protocol hemovigilance module. Atlanta, GA: Division of Healthcare Quality Promotion, National Center for Preparedness, Detection, and Control of Infectious Diseases, Centers for Disease Control and Prevention, 2009.
19. Koch C, Li L, Figueroa P, Mihaljevic T, Svensson L, Blackstone EH. Transfusion and pulmonary morbidity after cardiac surgery. Ann Thorac Surg. 2009;88(5):1410-1418.
20. Keller-Stanislawski B, Reil A, Gunay S, Funk MB. Frequency and severity of transfusion-related acute lung injury - German haemovigilance data (2006-2007). Vox Sang. 2010;98(1):70-77.
21. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion. 2007;47(4):599-607.
22. Silliman CC, Fung YL, Ball JB, Khan SY. Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. Blood Rev. 2009;23(6):245-255.
23. Middelburg RA, van Stein D, Briet E, van der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion. 2008;48(10):2167-2176.
24. Reil A, Keller-Stanislawski B, Gunay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang. 2008;95(4):313-317.
25. Maślanka K, Michur H, Zupanska B, Uhrynowska M, Nowak J. Leucocyte antibodies in blood donors and a look back on recipients of their blood components. Vox Sang. 2007;92(3):247-249. (Pubitemid 46365030)
26. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion. 2009;49(9):1825-1835.
27. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA. 2002;287(15):1968-1971.
28. Van Buren NL, Stroncek DF, Clay ME, McCullough J, Dalmasso AP. Transfusion-related acute lung injury caused by an NB2 granulocyte-specific antibody in a patient with thrombotic thrombocytopenic purpura. Transfusion. 1990;30(1):42-45. (Pubitemid 20037304)
29. Rana R, Afessa B, Keegan MT, et al. Evidence-based red cell transfusion in the critically ill: quality improvement using computerized physician order entry. Crit Care Med. 2006;34(7):1892-1897.
30. Nakazawa H, Ohnishi H, Okazaki H, et al. Impact of fresh-frozen plasma from male-only donors versus mixed-sex donors on postoperative respiratory function in surgical patients: a prospective case-controlled study. Transfusion. 2009;49(11):2434-2441.
31. Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion. 2001;41:317-322.
32. Welsby IJ, Troughton M, Phillips-Bute B, et al. The relationship of plasma transfusion from female and male donors with outcome after cardiac surgery. J Thorac Cardiovasc Surg. 2010;140(6):1353-1360.
33. Danielson C, Benjamin RJ, Mangano MM, Mills CJ, Waxman DA. Pulmonary pathology of rapidly fatal transfusion-related acute lung injury reveals minimal evidence of diffuse alveolar damage or alveolar granulocyte infiltration. Transfusion. 2008;48(11):2401-2408.
34. Jensen HM, Galante JM, Kysar PE, Tolstikov VV, Reddy KJ, Holland PV. TRALI is due to pulmonary venule damage from leucocytes with cholesterol crystal formation. Vox Sang. 2010;98(2):130-137.
35. Kao GS, Wood IG, Dorfman DM, Milford EL, Benjamin RJ. Investigations into the role of anti-HLA class II antibodies in TRALI. Transfusion. 2003;43(2):185-191. (Pubitemid 36207298)
36. Abraham E. Neutrophils and acute lung injury. Crit Care Med. 2003;31(4 suppl):S195-199.
37. Till GO, Johnson KJ, Kunkel R, Ward PA. Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest. 1982;69(5):1126-1135.
38. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6(3):173-182.
39. Stowell SR, Karmakar S, Arthur CM, et al. Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane. Mol Biol Cell. 2009;20(5):1408-1418.
40. Stowell SR, Karmakar S, Stowell CJ, Dias-Baruffi M, McEver RP, Cummings RD. Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood. 2007;109(1):219-227.
41. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004;61(3):481-497.
42. Woodfin A, Voisin MB, Nourshargh S. Recent developments and complexities in neutrophil transmigration. Curr Opin Hematol. 2010;17(1):9-17.
43. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell. 1989;56(6):1033-1044.
44. Moore KL, Patel KD, Bruehl RE, et al. P-selectin glycoprotein ligand-1 mediates rolling of human neutrophils on P-selectin. J Cell Biol. 1995;128(4):661-671.
45. Kernoff PB, Durrant IJ, Rizza CR, Wright FW. Severe allergic pulmonary oedema after plasma transfusion. Br J Haematol. 1972;23(6):777-781.
46. Wolf CF, Canale VC. Fatal pulmonary hypersensitivity reaction to HL-A incompatible blood transfusion: report of a case and review of the literature. Transfusion. 1976;16(2):135-140.
47. Silliman CC, Curtis BR, Kopko PM, et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a 2-event in vitro model. Blood. 2007;109(4):1752-1755.
48. Takahashi D, Fujihara M, Azuma H, et al. Stimulation of human neutrophils with sera containing HLA Class I alloantibody causes preferential degranulation of azurophilic granules and secretory vesicles. Vox Sang. 2010;98:560-566.
49. Nishimura M, Hashimoto S, Takanashi M, Okazaki H, Satake M, Nakajima K. Role of antihuman leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transfus Med. 2007;17(2):129-134.
50. Wakamoto S, Fujihara M, Sakagawa H, et al. Endothelial permeability is increased by the supernatant of peripheral blood mononuclear cells stimulated with HLA Class II antibody. Transfusion. 2008;48(10):2060-2068.
51. Nakajima F, Nishimura M, Hashimoto S, Okazaki H, Tadokoro K. Role of anti-Nak(a) antibody, monocytes and platelets in the development of transfusion related acute lung injury. Vox Sang. 2008;95(4):318-323.
52. Nishimura M, Ishikawa Y, Satake M. Activation of polymorphonuclear neutrophils by immune complex: possible involvement in development of transfusion-related acute lung injury. Transfus Med. 2004;14(5):359-367.
53. Silliman CC, Dickey WO, Paterson AJ, et al. Analysis of the priming activity of lipids generated during routine storage of platelet concentrates. Transfusion. 1996;36(2):133-139.
54. Vlaar AP, Hofstra JJ, Levi M, et al. Supernatant of aged erythrocytes causes lung inflammation and coagulopathy in a "2-hit" in vivo syngeneic transfusion model. Anesthesiology. 2010;113(1):92-103.
55. Sachs UJ, Wasel W, Bein G, Berghofer H, Schilow W, Heiden M. Supernatants from stored leukodepleted packed red blood cells do not regularly exhibit changes in their (lyso-)phosphatidylcholine composition and do not cause TRALI in an ex vivo rat lung model [abstract]. Vox Sang. 2010;99(S2):456.
56. Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion. 1997;37(7):719-726.
57. Partrick DA, Moore EE, Moore FA, Barnett CC, Silliman CC. Lipid mediators up-regulate CD11b and prime for concordant superoxide and elastase release in human neutrophils. J Trauma. 1997;43(2):297-302; discussion 302-303.
58. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest. 1998;101(7):1458-1467.
59. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455-2462.
60. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22:307-328.
61. Mangalmurti NS, Xiong Z, Hulver M, et al. Loss of red cell chemokine scavenging promotes transfusion-related lung inflammation. Blood. 2009;113(5):1158-1166.
62. Reichel CA, Rehberg M, Lerchenberger M, et al. Ccl2 and Ccl3 mediate neutrophil recruitment via induction of protein synthesis and generation of lipid mediators. Arterioscler Thromb Vasc Biol. 2009;29(11):1787-1793.
63. Zarbock A, Ley K. Mechanisms and consequences of neutrophil interaction with the endothelium. Am J Pathol. 2008;172(1):1-7.
64. Ramachandran V, Williams M, Yago T, Schmidtke DW, McEver RP. Dynamic alterations of membrane tethers stabilize leukocyte rolling on P-selectin. Proc Natl Acad Sci U S A. 2004;101(37):13519-13524.
65. Darbonne WC, Rice GC, Mohler MA, et al. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest. 1991;88(4):1362-1369.
66. Seeger W, Schneider U, Kreusler B, et al. Reproduction of transfusion related acute lung injury in an ex vivo lung model. Blood. 1990;76(7):1438-1444.
67. Grimminger F, Kreusler B, Schneider U, et al. Human leukoagglutinating antibody evokes cooperative leukotriene synthesis in pulmonary microvasculature: model of transfusion-related acute lung injury. Circ Res. 1991;68(2):503-512.
68. Sachs UJ, Hattar K, Weissmann N, et al. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood. 2006;107(3):1217-1219.
69. Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion. 2003;43(5):633-640.
70. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A 2-insult in vitro model of PMN mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol. 2002;283(6):C1592-1603.
71. Kelher MR, Masuno T, Moore EE, et al. Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood. 2009;113(9):2079-2087.
72. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest. 2006;116(6):1615-1623.
73. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a 2-event model of transfusion-related acute lung injury. J Clin Invest. 2009;119(11):3450-3461.
74. Partrick DA, Moore EE, Fullerton DA, Barnett CC, Jr., Meldrum DR, Silliman CC. Cardiopulmonary bypass renders patients at risk for multiple organ failure via early neutrophil priming and late neutrophil disability. J Surg Res. 1999;86:42-49.
75. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood. 1990;75(3):550-554.
76. Partrick DA, Moore EE, Offner PJ, Johnson JL, Tamura DY, Silliman CC. Hypertonic saline activates lipid-primed human neutrophils for enhanced elastase release. J Trauma. 1998;44(4):592-597; discussion, 598.
77. Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49(3):440-452.
78. Murphy MF, Navarrete C, Massey E. Donor screening as a TRALI risk reduction strategy. Transfusion. 2009;49(9):1779-1782.
79. Kleinman S, Grossman B, Kopko P. A national survey of transfusion-related acute lung injury reduction policies for platelets and plasma in the United States. Transfusion. 2010;50(6):1312-1321.
80. Bierling P, Bux J, Curtis B, et al. Recommendations of the ISBTWorking Party on Granulocyte Immunobiology for leucocyte antibody screening in the investigation and prevention of antibody-mediated transfusion-related acute lung injury. Vox Sang. 2009;96(3):266-269.
81. AABB. Association bulletin #07-03. http://www.aabb.org/resources/ publications/bulletins/Pages/ab07-03.aspx. Accessed October 29, 2010.
82. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev. 2006;20(4):273-282.
83. Eder AE, Herron RM, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion. 2010;50(8):1732-1742.
84. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/ detergent plasma. Transfusion. 2005;45(10):1628-1631.
85. Sinnott P, Bodger S, Gupta A, Brophy M. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet. 2004;31(6):271-274.